Global Bacteriophage Therapy Market, by Targeted Bacteria (Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella, and Others), by Route of Administration (Oral, Topical, and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Increasing prevalence and awareness of antimicrobial-resistant infection is driving adoption of phage therapy for treatment of such infections which is expected to drive the market growth. For instance, according to World Health Organization, in 2016, around 490,000 people developed multi-drug resistant TB globally. This drug resistance has also impacted the management and treatment of other infections such as malaria and HIV. As a result there is increasing inclination among the populace towards non-traditional therapeutics for treating such infections.

Manufacturers are focusing on the development of an effective phage therapy to control such drug resistant infection. Moreover, increasing approvals from drug regulatory authorities for development phage therapy candidates are contributing to growth of the market. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy. The application for the clinical study has been submitted by physician-scientists at the University Of California San Diego School Of Medicine. Following the U.S. FDA approval, the company plans to initiate phase I/II clinical trial study to test AB-SA01, an experimental bacteriophage combination for treatment of participants with ventricular assist devices (VADs) infected by resistant Staphylococcus aureus (S. aureus).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/bacteriophages-therapy-market-2752

Browse 146 Pages and in-depth TOC on ‘Bacteriophage Therapy Market’- Global Bacteriophage Therapy Market, by Targeted Bacteria (Escherichia coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella and Others), by Route of Administration (Oral, Topical and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

North America is expected to hold a dominant position in the bacteriophage therapy market over the forecast period, owing to rising prevalence of antibiotic resistant infections in the region. For instance, according to the Centers for Disease Control and Prevention, in 2018, around 2 million people had antibiotic-resistant infection and around 23,000 people died from antibiotic resistant infections each year in the U.S.

Europe is expected to witness growth in the bacteriophage therapy market over the forecast period due to expansion of manufacturing facility for producing bacteriophage therapy, and rising research and development activities by market players in the region. For instance, in June 2015, AmpliPhi BioSciences Corporation, developer of bacteriophage-based antibacterial therapies, received the Good Manufacturing Practices (cGMP) certification from JAZMP, agency of the Republic of Slovenia for Medicinal Products and Medical Devices, for the manufacturing of bacteriophages (Staphylococcus aureus and Pseudomonas aeruginosa) at its facility in Slovenia.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2752

Key Takeaways of the Bacteriophage Therapy Market:

The global bacteriophage therapy market is expected to grow over the forecast period owing to inorganic growth strategies such as partnerships, collaborations, acquisitions among market players. For instance, in March 2018, AmpliPhi Biosciences Corporation (Armata Pharamceutical Inc.) collaborated with the U.S. Department of Veterans Affairs for expanding access for its investigational bacteriophage candidates, AB-SA01 and AB-PA01, within VA Palo Alto Health Care System.

Key players operating in the global bacteriophage therapy market are Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, and ContraFect Corporation.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2752

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737